李氏大药厂中期报告2023

2 3 中 期 报 告 I n t e r i m R e p o r t 2 0 仅供识别 INTERIMFINANCIALSTATEMENTS TheDirectorspresentherewiththeunauditedconsolidatedinterimfinancialresults(the“InterimResults”)oftheGroupforthesixmonthsended30June2023,togetherwiththecomparativefiguresforthecorrespondingperiodin2022.TheInterimResultsareunaudited,buthavebeenreviewedbytheCompany’sauditor,ConfuciusInternationalCPALimited(the“Auditor”)inaccordancewithHongKongStandardonReviewEngagements2410“ReviewofInterimFinancialInformationPerformedbytheIndependentAuditoroftheEntity”issuedbytheHongKongInstituteofCertifiedPublicAccountants(“HKICPA”).TheAuditCommitteehasalsoreviewedwiththemanagementandtheAuditortheInterimResultsbeforerecommendingittotheBoardforapproval. 中期财务报表 董事谨此呈报本集团截至二零二三年六月三十日止六个月之未经审核综合中期财务业绩（“中期业绩”）连同二零二二年同期之比较数字。中期业绩未经审核，惟获本公司核数师天健国际会计师事务所有限公司 （“核数师”）按照香港会计师公会颁布之《香港审阅工作准则》第2410号“实体的独立核数师对中期财务资料的审阅”进行审阅。审核委员会于向董事会推荐中期业绩以供批准前，亦已与管理层及核数师审阅中期业绩。 BUSINESSREVIEW RevenueandProfit Duringthefirst-half2023,theGrouphasfaceddiversechallenges,includingpriceandmarginpressureresultingfromtheloweredpriceofcertainproductsinexchangeforbeingincludedinthenationalreimbursementscheme,theloweredmarginoftheproductundernationalvolume-basedprocurementprogramandthedepreciationoftheRenminbiduringtheperiodunderreview,whichencompassitsoperations.Nevertheless,havingproductsincludedinthenationalreimbursementschemeandnationalvolume-basedprocurementprogrampresentsbothrisksandopportunities,asithasopenedupthepotentialforincreasedmarketaccessandvolume.Inaddition,theGrouphasmadesignificantstridesinimprovingitsoperationalefficiencyandtoreducecosts.Asaresultofthediligentefforts,theGrouphassuccessfullymaintainedprofitabilityduringthisperiodunderreview. First-half2023revenueoftheGrouptotalledHK$512,308,000(First-half2022:HK$649,166,000),adecreaseof21.1%comparedtothesameperiodlastyearwhichismainlyattributabletotheimpactoftheexpirationofproductlicenseandthedecliningproducts,andthedepreciationoftheRenminbi.Nevertheless,theGrouphaseffectivelyshowcasedsalesgrowthacrossitsavailableproductrange.Ferplex®,Bredinin™,Sancuso®andTrittico®haveshownsignificantgrowthduringthefirst-half2023,withimpressivegrowthratesof39.6%,43.4%,197.4%and176.3%,respectively.Inaddition,twoothernewergenericproducts,namelyFondaparinuxSodiumInjectionandSodiumPhenylbutyrateGranules,recordedsmallersalesamountsbuthaveshownhighgrowthpotentialinthemarketandgrew584.1%and83.5%,respectively. 业务回顾 收益及溢利 二零二三年上半年，本集团面对不同挑战，包括将若干产品降价以配合纳入国家医保计划，在国家集中带量采购计划下产品利润下降，以及回顾期内人民币贬值，对其业务营运造成价格及利润压力。然而，产品获纳入国家医保计划及国家集中带量采购计划，风险与机会并存，有望扩大市场接触面及提升销量。此外，本集团大力提高营运效益及降低成本。几经努力，本集团于本回顾期间成功保持盈利。 二零二三年上半年，本集团的收益合共为512,308,000港元（二零二二年上半年：649,166,000港元），较去年同期减少21.1%，主要是受到产品权限届满、销量下降的产品及人民币贬值的影响。然而，本集团的现存产品组合均见实际销售增长。二零二三年上半年，《菲普利®》、《布累迪宁™》、《善可舒®》及 《曲特恪®》增长显着，增长率甚为可观，分别达39.6%、43.4%、197.4%及 176.3%。此外，另外两款较新的仿制产品磺达肝癸钠注射液及苯丁酸钠颗粒则录得录得较小的销售额，惟已显现高增长的市场潜力，分别增长584.1%及83.5%。 Salesoflicensed-inproductswerepredominantinthepast,buttherehasbeenashifttowardsincreasedsalesofproprietaryandgenericproductsstartingfromthebeginningof2023.Salesoflicensed-inproductsinthefirst-half2023accountedfor46.9%(First-half2022:61.2%)oftheGroup’srevenuewhilesalesofproprietaryandgenericproductsinthefirst-half2023contributed53.1%(First-half2022:38.8%)oftheGroup’srevenue. First-half2023grossprofitoftheGroupwasHK$284,463,000(First-half2022:HK$419,478,000),adecreaseof32.2%comparedtothesameperiodlastyear.TheGroup’soverallgrossprofitmarginwas55.5%,decreasedby9.1percentagepointsasto64.6%achievedinthefirst-half2022.TheGrouphasshiftedtowardsofferingabroaderrangeofproducts,includinglower-margingenericproductsundernationalreimbursementschemeandnationalvolume-basedprocurementprogram,whichcausedadecreaseintheoverallgrossprofitmargin. R&Dexpensesrepresentednewdrugsdevelopmentinmajortherapeuticareassuchascardiovascular,womanhealth,paediatrics,rarediseases,dermatologyandobstetrics,aswellasinoncologyunderaseparateR&DarmwithintheGroup.Duringthefirst-half2023,theGroupcontinuestooptimisetheresourcesallocationamongprioritisedR&Dprojectsandtopersistincost-savingefforts.AnaggregateofHK$113,634,000hasbeenspentinthefirst-half2023(First-half2022:HK$206,517,000),decreasedby45.0%comparedtothesameperiodlastyearandrepresented22.2%tothecorrespondingrevenuefortheperiod(First-half2022:31.8%).AmongwhichHK$48,798,000(First-half2022:HK$116,590,000)hasbeenrecognisedasexpensesandHK$64,836,000(First-half2022:HK$89,927,000)hasbeencapitalisedasintangibleassets.Asexpected,theGroupstrategicallyselectsnewinitiativeswhenpreviousR&Dprojectsovertimereachcompletion,thereisareductionintheR&Dexpenditureincurredduringtheperiodunderreview. 销售引进产品在过去占主导地位，惟自二零二三年年初开始，重心转向专利及仿制产品，其销售额有所增长。引进产品于二零二三年上半年的销售额占本集团收益46.9%（二零二二年上半年：61.2%），而专利及仿制产品二零二三年上半年的销售额占本集团收益53.1%（二零二二年上半年：38.8%）。 二零二三年上半年，本集团录得毛利 284,463,000港元（二零二二年上半年： 419,478,000港元），较去年同期减少 32.2%。本集团整体毛利率为55.5%，较二零二二年上半年的64.6%下降9.1个百分点。本集团已转向提供更广泛的产品，包括国家医保计划及国家集中带量采购计划下利润较低的仿制产品，导致毛利率整体下降。 研发费用来自心血管、女性健康、儿科、罕见病、皮肤科及产科等各个主要治疗领域的新药开发，以及本集团内的独立肿瘤科研发分支。二零二三年上半年，本集团继续优化各优先研发项目